The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright & Co. on September 6, 2024. The analyst firm set a price target for $7.50 expecting AKBA to rise to within 12 months (a possible 435.71% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Akebia Therapeutics (NASDAQ:AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics reiterated their buy rating.

The last upgrade for Akebia Therapeutics Inc happened on August 28, 2023 when HC Wainwright & Co. raised their price target to $3.75. HC Wainwright & Co. previously had a neutral for Akebia Therapeutics Inc.

The last downgrade for Akebia Therapeutics Inc happened on March 31, 2022 when HC Wainwright & Co. changed their price target from $10 to $2 for Akebia Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a reiterated with a price target of $7.50 to $7.50. The current price Akebia Therapeutics (AKBA) is trading at is $1.40, which is out of the analyst’s predicted range.